Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 12/20 | 0.67 |
| ▸ | PDE4A | P27815 | 11/20 | 0.67 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.67 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.67 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL7437475 | 0.93 | PDE5A (0.59) | PDE5APDE4APDE4BPDE4CPDE4D | |
| Maleic Acid SCHEMBL7437465 | 0.93 | PDE5A (0.59) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7432167 | 0.81 | PDE5A (0.79) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7436549 | 0.81 | PDE5A (0.79) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7392696 | 0.81 | PDE5A (1.00) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7389735 | 0.78 | PDE5A (0.69) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7397039 | 0.76 | PDE5A (0.66) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7440118 | 0.74 | PDE5A (0.72) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7451032 | 0.74 | PDE5A (1.00) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7390028 | 0.74 | PDE4A (0.92) | PDE5APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778690-B1 | Substituted 8-aminoalkoxi-xanthines, method for the production thereof and use thereof as medicaments | SANOFI AVENTIS DEUTSCHLAND (DE) | 2012-08-22 | — | — | EP | claimed |
| US-7879864-B2 | dipeptidyl peptidase IV inhibitors such as 8-(2-Amino-2-methylpropoxy)-3-methyl-7-(3-methylbut-2-enyl)-1-(2-oxo-2-phenylethyl)-3,7-dihydropurine-2,6-dione, used for the treatment of elevated blood glucose levels and metabolic disorders; antidiabetic agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-02-01 | — | — | US | claimed |
| US-20070299090-A1 | SUBSTITUTED 8-AMINOALKOXY-XANTHINE COMPOUNDS AND COMPOSITIONS USEFUL IN THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-12-27 | — | — | US | claimed |
| EP-1778690-A1 | SUBSTITUTED 8-AMINOALKOXI-XANTHINES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2007-05-02 | — | — | EP | claimed |
| WO-2006018117-A1 | SUBSTITUTED 8-AMINOALKOXI-XANTHINES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-02-23 | — | — | WO | claimed |
| EP-1778690-B1 | Substituted 8-aminoalkoxi-xanthines, method for the production thereof and use thereof as medicaments | SANOFI AVENTIS DEUTSCHLAND (DE) | 2012-08-22 | — | — | EP | disclosed |
| US-7879864-B2 | dipeptidyl peptidase IV inhibitors such as 8-(2-Amino-2-methylpropoxy)-3-methyl-7-(3-methylbut-2-enyl)-1-(2-oxo-2-phenylethyl)-3,7-dihydropurine-2,6-dione, used for the treatment of elevated blood glucose levels and metabolic disorders; antidiabetic agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-02-01 | — | — | US | disclosed |
| US-20070299090-A1 | SUBSTITUTED 8-AMINOALKOXY-XANTHINE COMPOUNDS AND COMPOSITIONS USEFUL IN THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-12-27 | — | — | US | disclosed |
| EP-1778690-A1 | SUBSTITUTED 8-AMINOALKOXI-XANTHINES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006018117-A1 | SUBSTITUTED 8-AMINOALKOXI-XANTHINES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-02-23 | — | — | WO | disclosed |
| EP-0550570-A1 | XANTHINE DERIVATIVES | Beecham Group p.l.c. (GB) | 1993-07-14 | — | — | EP | disclosed |
| WO-1992005175-A1 | XANTHINE DERIVATIVES | BEECHAM GROUP PLC (GB) | 1992-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299090-A1 | SUBSTITUTED 8-AMINOALKOXY-XANTHINE COMPOUNDS AND COMPOSITIONS USEFUL IN THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES | DPP8, DPP4, DPP7 | PDE5A 554/4885PDE4A 258/4885PDE4B 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.